Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor

Immunological Reviews

Volumn 163, Issue , 1998, Pages 89-120

  Tzartos, Socrates J ^a   Barkas, Tom ^b   Cung, M Thong ^c   Mamalaki, Avgi ^a   Marraud, Michel ^c   Orlewski, Piotr ^c   Papanastasiou, Danai ^a   Sakarellos, Constantinos ^d   Sakarellos Daitsiotis, Maria ^d   Tsantili, Panayota ^a   Tsikaris, Vassilios ^d  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

^b Juniper House   (United Kingdom)

^c LAB DE CHIM PHYS MACROMOLECULAIRE   (France)

^d UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; NICOTINIC RECEPTOR;

ANTIGENICITY; AUTOIMMUNE DISEASE; CHANNEL GATING; HUMAN; MOLECULAR MIMICRY; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; AUTOANTIGENS; BINDING SITES; CROSS REACTIONS; CYTOPLASM; HUMANS; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; PROTEIN CONFORMATION; RECEPTORS, NICOTINIC;

EID: 17344372846     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1998.tb01190.x     Document Type: Review

References (239)

1. Galzi JL, Changeux JP. Neurotransmitter-gated ion channels as unconventional allosteric proteins. Curr Opin Struct Biol 1994;4:554-565.
2. Karlin A, Akabas MH. Towards a structural basis for the function of nicotinic acetylcholine receptors and their cousins. Neuron 1995;15:1231-1244.
3. Lindstrom J. Neuronal nicotinic acetylcholine receptors. In: Narahashi T, ed. Ion channels. Vol 4. New York: Plenum Press; 1996. p. 377-450.
4. Gotti C, Fornasari D, Clementi F. Human neuronal nicotinic receptors. Prog Neurobiol 1997;53:199-237.
5. Lenovere N, Changeux JP. Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells. J Mol Evol 1995;40:155-172.
6. Arias HR. Topology of ligand binding sites on the nicotinic acetylcholine receptor. Brain Res Brain Res Rev 1997;25:133-191.
7. Loring RH. The molecular basis of curaremimetic snake neurotoxin specificity for neuronal nicotinic receptor subtypes. J Toxicol Toxin Rev 1993;12:105-153.
8. Tzartos SJ, Remoundos MS. Fine localization of the major α-bungarotoxin binding site to residues α189-195 of the Torpedo acetylcholine receptor. Residues 189, 190 and 195 are indispensable for binding. J Biol Chem 1990;265:21462-21467.
9. Griesmann GE, McCormick DJ, Deaizpurua HJ, Lennon VA. Alpha-bungarotoxin binds to human acetylcholine receptor alpha-subunit peptide-185-199 in solution and solid phase but not to peptide-125-147 and peptide-389-409. J Neurochem 1990;54:1541-1547.
10. McLane KE, Wu XD, Diethelm B, Conti-Tronconi BM. Structural determinants of alpha-bungarotoxin binding to the sequence segment 181-200 of the muscle nicotinic acetylcholine receptor alpha-subunit - effects of cysteine/cystine modification and species-specific amino acid substitutions. Biochemistry 1991;30:4925-4934.
11. Mishina M, et al. Expression of functional acetylcholine receptor from cloned cDNAs. Nature 1984;307:604-608.
12. Kubalek E, Ralston S, Lindstrom J, Unwin N. Location of subunits within the acetylcholine receptor by electron image analysis of tubular crystals from Torpedo marmorata. J Cell Biol 1987;105:9-18.
13. Hucho F, Oberthur W, Lottspeich F. The ion channel of the nicotinic acetylcholine receptor is formed by the homologous helices M II of the receptor subunits. FEBS Lett 1986;205:137-142.
14. Giraudat J, Dennis M, Heidmann T, Haumont P-Y, Lederer F, Changeux J-P. Structure of the high-affinity binding site for noncompetitive blockers of the acetylcholine receptor: [3-H]chlorpromazine labels homologous residues in the β and δ chains. Biochemistry 1987;26:2410-2418.
15. Dipaola M, Kao PN, Karlin A. Mapping the alpha-subunit site photolabeled by the noncompetitive inhibitor [3H]quinacrine azide in the active state of the nicotinic acetylcholine receptor. J Biol Chem 1990;265:11017-11029.
16. Zhang H, Karlin A. Identification of acetylcholine receptor channel-lining residues in the M1 segment of the β-subunit. Biochemistry 1997;36:15856-15864.
17. Brisson A, Unwin PN. Tubular crystals of acetylcholine receptor. J Cell Biol 1984;99:1202-1211.
18. Mitra AK, McCarthy MP, Stroud RM. Three-dimensional structure of the nicotinic acetylcholine receptor and location of the major associated 43-Kd cytoskeletal protein, determined at 22-Å by low dose electron microscopy and X-ray diffraction to 12.5 Å. J Cell Biol 1989;109:755-774.
19. Toyoshima C, Unwin N. Three-dimensional structure of the acetylcholine receptor by cryoelectron microscopy and helical image reconstruction. J Cell Biol 1990;111:2623-2635.
20. Unwin N. Nicotinic acetylcholine receptor at 9-angstrom resolution. J Mol Biol 1993;229:1101-1124.
21. Unwin N. Acetylcholine receptor channel imaged in the open state. Nature 1995;373:37-43.
22. Unwin N. Projection structure of the nicotinic acetylcholine receptor: distinct conformations of the alpha subunits. J Mol Biol 1996;257:586-596.
23. Lindstrom J, Shelton D, Fugii Y. Myasthenia gravis. Adv Immunol 1988;42:233-284.
24. Tournier-Lasserve E, Bach JF. The immunogenetics of myasthenia gravis, multiple sclerosis and their animal models. J Neuroimmunol 1993;47:103-114.
25. Drachman DB. Medical progress - myasthenia gravis. N Engl J Med 1994;330:1797-1810.
26. Conti-Fine B, Protti MP, Bellone M, Howard JF, eds. Myasthenia gravis: the immunobiology of an autoimmune disease. New York: Springer; 1997.
27. Marx A, Wilisch A, Schultz A, Gattenlohner S, Nenninger R, Mullerhermelink HK. Pathogenesis of myasthenia gravis. Virchows Arch 1997;430:355-364.
28. Ann N Y Acad Sci IX International Conference on Myasthenia Gravis and Related Disorders; 1998 (In press).
29. Patrick J, Lindstrom JL. Autoimmune response to acetylcholine receptors. Science 1973;180:871-872.
30. Fambrough DM, Drachman DB, Satiamurti S. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science 1973;181:293-295.
31. Toyka KV, Drachman DB, Pestronk A, Kao I. Myasthenia gravis: passive transfer from man to mouse. Science 1975;190:397-399.
32. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane D. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates and diagnostic value. Neurology 1976;26:1054-1059.
33. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985;48: 1246-1252.
34. Morel E, Eymard B, Vernet-der Garabedian B, Pannier C, Dulac O, Bach JF. Neonatal myasthenia gravis - a new clinical and immunologic appraisal on 30 cases. Neurology 1988;38:138-142.
35. Lefvert AK, Pirskanen R, Svanborg E. Anti-idiotypic antibodies, acetylcholine receptor antibodies and disturbed neuromuscular function in healthy relatives to patients with myasthenia gravis. J Neuroimmunol 1985;9:41-53.
36. Oosterhuis HJ. Diagnosis and differential diagnosis. In: DeBaets MH, Oosterhuis HJGH, eds. Myasthenia gravis. Boca Raton: CRC Press; 1993. p. 203-234.
37. Oosterhuis HJ, ed. Myasthenia gravis. Clin Neurol Neurosurg Monogr [Edinburgh: Churchill Livingstone] 1984;5:1-269.
38. Heinemann S, Bevan S, Kullberg R, Lindstrom J, Rice J. Modulation of the acetylcholine receptor by anti-receptor antibodies. Proc Natl Acad Sci USA 1977;74:3090-3094.
39. Engel AG. Myasthenia gravis and myasthenic syndromes. Ann Neurol 1984;16:519-533.
40. Harvey AL, Barkas T, Harrison R, Lunt GG. Inhibition of receptor function in cultured chick myotubes by antiserum to purified Torpedo acetylcholine receptor and myasthenic sera. In: Lunt GG, Marchbanks RM, eds. The biochemistry of myasthenia gravis and muscular dystrophy. London: Academic Press; 1978. p. 167-175.
41. Drachman DB, Adams RN, Josifek LF, Self SG. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med 1982;307:769-775.
42. Morel E, Vernet-der Garabedian B, Eymard B, Raimond F, Bustarret F-A, Bach J-F. Binding and blocking antibodies to the human acetylcholine receptor: are they selected in various myasthenia gravis forms? Immunol Res 1988;7:212-217.
43. Conti-Tronconi BM, Mclane KE, Raftery MA, Grando SA, Protti MP. The nicotinic acetylcholine receptor - structure and autoimmune pathology. Crit Rev Biochem Mol Biol 1994;29:69-123.
44. Christadoss P. Immunogenetics of experimental autoimmune myasthenia gravis. Crit Rev Immunol 1989;9:247-278.
45. Vincent A. Experimental autoimmune myasthenia gravis. In: Cohen I, Miller A, eds. Autoimmune disease models. a guidebook. Orlando: Academic Press; 1994. p. 83-106.
46. Souroujon MC, Fuchs S. Experimental autoimmune myasthenia gravis. In: Lefkovits I, ed. Immunology methods manual. Academic Press; 1997. p.1763-1773.
47. Shelton GD, Cardinet III GH, Lindstrom JM. Canine and human myasthenia gravis autoantibodies recognize similar regions on the acetylcholine receptor. Neurology 1988;38:1417-1423.
48. Russell AS, Lindstrom JM. Penicillamine-induced myasthenia gravis associated with antibodies to acetylcholine receptor. Neurology 1978;28:847-849.
49. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody characteristics in myasthenia gravis. II. Patients with penicillamine-induced myasthenia or idiopathic myasthenia of recent onset. Clin Exp Immunol 1982;49:266-272.
50. Tzartos SJ, et al. Fine antigenic specificities of antibodies in sera from patients with D-penicillamine-induced myasthenia gravis. Clin Exp Immunol 1988;74:80-86.
51. Scadding GK, Vincent A, Newsom-Davis J, Henry K. Acetylcholine receptor antibody synthesis by thymic lymphocytes: correlation with thymic histology. Neurology 1981;31:935-943.
52. Wekerle H, Ketelsen U-P, Zurn AD, Fulpius BW Intrathymic pathogenesis of myasthenia gravis: transient expression of acetylcholine receptors on thymus-derived myogenic cells. Eur J Immunol 1978;8:579-582.
53. Drachman DB. Immunotherapy in neuromuscular disorders: current and future strategies. Muscle Nerve 1996;19:1239-1251.
54. Hohlfeld R, Melms A, Toyka KV, Drachman DB. Therapy for myasthenia gravis and myasthenic syndromes. In: Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C, eds. neurological disorders: course and treatment. San Diego: Academic Press; 1996. p. 947-964.
55. Antozzi C, Berta E, Confalonieri P, Zuffi M, Cornelio F, Mantegazza R. Protein-A immunoadsorption in immunosuppression-resistant myasthenia gravis. Lancet 1994;343:124.
56. Berta E, et al. Removal of anti-acetylcholine receptor antibodies by protein-A immunoadsorption in myasthenia gravis. Int J Artif Organs 1994;17:603-608.
57. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997;41:789-796.
58. Koffman BM, Dalakas MC. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerve 1997;20:1102-1107.
59. Penn AS, Richman DP, Ruff RL, Lennon VA, eds. Myasthenia gravis and related disorders: experimental and clinical aspects. Ann N Y Acad Sci 1993;681:1-611.
60. DeBaets MH, Oosterhuis HJ, eds. Myasthenia gravis. Boca Raton: CRC Press; 1993.
61. Lisak RP, ed. Handbook of myasthenia gravis and myasthenic syndromes. New York: Dekker; 1994.
62. Berrih-Aknin S. Myasthenia gravis, a model of organ-specific autoimmune disease. J Autoimmun 1995;8:139-143.
63. Lindstrom JM, Lennon VA, Seybold ME, Whittingham S. Experimental autoimmune myasthenia gravis and myasthenia gravis: biochemical and immunochemical aspects. Ann N Y Acad Sci 1976;274:254-274.
64. Froehner SC. Identification of exposed and buried determinants of the membrane-bound acetylcholine receptor from Torpedo californica. Biochemistry 1981;20:4905-4915.
65. Sargent P, Hedges B, Tsavaler L, Clemmons L, Tzartos SJ, Lindstrom J. The structure and transmembrane nature of the acetylcholine receptor in amphibian skeletal muscle as revealed by cross-reacting monoclonal antibodies. J Cell Biol 1984;98:609-618.
66. Tzartos SJ, Lindstrom JL. Monoclonal antibodies to probe acetylcholine receptor structure: localization of the MIR and detection of similarities between subunits. Proc Natl Acad Sci USA 1980;77:755-759.
67. Tzartos SJ, et al. The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies. Mol Neurobiol 1991;5:1-29.
68. Lennon VA, Griesmann GE. Evidence against acetylcholine receptor having a main immunogenic region as target for autoantibodies in myasthenia gravis. Neurology 1989;39:1069-1076.
69. Zhang Y, Barkas T, Juillerat M, Schwendimann B, Wekerle H. T cell epitopes in EAMG of the rat: strain-specific epitopes and cross-reaction between two distinct segments of the α chain of the nicotinic acetylcholine receptor (Torpedo californica). Eur J Immunol 1988;18:551-557.
70. Willcox N. Myasthenia gravis. Curr Opin Immunol 1993;5:910-917.
71. Tzartos SJ, Langeberg L, Hochschwender S, Swanson L, Lindstrom J. Characteristics of monoclonal antibodies to denatured Torpedo and to native calf acetylcholine receptors: species, subunit and region specificity. J Neuroimmunol 1986;10:235-253.
72. Tzartos SJ. Studying the acetylcholine receptor with monoclonal antibodies. In: Osborne NN, ed. Current aspects in neurosciences. Vol 3. Houndmills: Macmillan Press; 1991. p. 195-226.
73. Ralston S, Sarin V, Thanh HL, Rivier J, Fox JL, Lindstrom J. Synthetic peptides used to locate the α-bungarotoxin binding site and immunogenic regions on α-subunits of the nicotinic acetylcholine receptor. Biochemistry 1987;26:3261-3266.
74. Das MK, Lindstrom J. Epitope mapping of antibodies to acetylcholine receptor- alpha subunits using peptides synthesized on polypropylene pegs. Biochemistry 1991;30:2470-2477.
75. Palace J, Vincent A, Beeson D, Newsom-Davis J. Immunogenicity of human recombinant acetylcholine receptor alpha subunit: cytoplasmic epitopes dominate the antibody response in four mouse strains. Autoimmunity 1994;18:113-119.
76. Graus YM, Vriesman PJ, DeBaets MH. Characterization of anti-acetylcholine receptor antibodies from mice differing in susceptibility for experimental autoimmune myasthenia gravis. Clin Exp Immunol 1993;92:506-513.
77. Souroujon MC, Pizzighella S, Mochly-Rosen D, Fuchs S. Antigenic specificity of acetylcholine receptor in developing muscle. J Neuroimmunol 1985;8:159-166.
78. Safran A, Neumann D, Fuchs S. Analysis of acetylcholine receptor phosphorylation sites using antibodies to synthetic peptides and monoclonal antibodies. EMBO J 1986;5:3175-3178.
79. Neumann D, Gershoni JM, Fridkin M, Fuchs S. Antibodies to synthetic peptides as probes for the binding site on the α-subunit of the acetylcholine receptor. Proc Natl Acad Sci USA 1985;82:3490-3493.
80. Criado M, Hochschwender S, Sarin V, Fox J, Lindstrom J. Evidence for unpredicted transmembrane domains in acetylcholine receptor subunits. Proc Natl Acad Sci USA 1985;82:2004-2008.
81. Lei SJ, Raftery MA, Conti-Tronconi BM. Monoclonal antibodies against synthetic sequences of the nicotinic receptor cross-react fully with the native receptor and reveal the transmembrane disposition of their epitopes. Biochemistry 1993;32:91-100.
82. Lei SJ, Okita DK, Conti-Fine BM. Binding of monoclonal antibodies against the carboxyl terminal segment of the nicotinic receptor delta subunit suggests an unusual transmembrane disposition of this sequence region. Biochemistry 1995;34:6675-6688.
83. Pedersen SE, Cohen JB. D-tubocurarine binding sites are located at alpha-gamma and alpha-delta subunit interfaces of the nicotinic acetylcholine receptor. Proc Natl Acad Sci USA 1990;87:2785-2789.
84. Tzartos SJ, Rand DE, Einarson BE, Lindstrom JM. Mapping of surface structures of Electrophorus acetylcholine receptor using monoclonal antibodies. J Biol Chem 1981;256:8635-8645.
85. Ratnam M, Le Nguyen D, Rivier J, Sargent P, Lindstrom J. Transmembrane topography of the nicotinic acetylcholine receptor: immunochemical tests contradict theoretical predictions based on hydrophobicity profile. Biochemistry 1986;25:2633-2643.
86. Tzartos SJ, Kokla A, Walgrave S, Conti-Tronconi B. Localization of the main immunogenic region of human muscle acetylcholine receptor to residues 67-76 of the α-subunit. Proc Natl Acad Sci USA 1988;85:2899-2903.
87. Tzartos SJ, et al. The main immunogenic region of Torpedo electroplax and human muscle acetylcholine receptor. Localization and micro-heterogeneity revealed by the use of synthetic peptides. J Neurochem 1990;54:51-61.
88. Tzartos SJ, Remoundos MS. Precise epitope mapping of monoclonal antibodies to the cytoplasmic side of the acetylcholine receptor alpha subunit - dissecting a potentially myasthenogenic epitope. Eur J Biochem 1992;207:915-922.
89. Tzartos SJ, Valcana C, Kouvatsou R, Kokla A. The tyrosine phosphorylation site of the acetylcholine receptor beta-subunit is located in a highly immunogenic epitope implicated in channel function - antibody probes for beta-subunit phosphorylation and function. EMBO J 1993;12:5141-5149.
90. Tzartos SJ, Kouvatsou R, Tzartos E. Monoclonal antibodies as site-specific probes for the acetylcholine receptor δ-subunit tyrosine and serine phosphorylation sites. Eur J Biochem 1995;228:463-472.
91. Tzartos SJ, Tzartos E, Tzartos JS. Monoclonal antibodies against the acetylcholine receptor gamma-subunit as site specific probes for receptor tyrosine phosphorylation. FEBS Lett 1995;363:195-198.
92. Geysen HM, et al. Chemistry of antibody binding to a protein. Science 1987;235:1184-1190.
93. Hopp TP, Wood KR. Prediction of protein antigenic determinants from amino acid sequences. Proc Natl Acad Sci USA 1981;78:3824-3828.
94. Karplus PA, Schulz GE. Prediction of chain flexibility in proteins. Naturwissenschaften 1985;72:212-213.
95. Chou PY, Fasman GD. Prediction of beta-turns. Biophys J 1979;26:367-373.
96. Kirchner T, Tzartos S, Hoppe F, Schalke B, Wekerle H, Muller-Hermelink HK. Pathogenesis of myasthenia gravis. Acetylcholine receptor-related antigenic determinants in tumor-free thymuses and thymic epithelial tumors. Am J Pathol 1988;130:268-279.
97. Marx A, et al. Characterization of a protein with an acetylcholine receptor epitope from myasthenia gravis-associated thymomas. Lab Invest 1990;62:279-286.
98. Osborn M, Marx A, Kirchner T, Tzartos SJ, Plessman U, Weber K. A shared epitope in the acetylcholine receptor-alpha subunit and fast troponin I of skeletal muscle. Is it important for myasthenia gravis? Am J Pathol 1992;140:1215-1223.
99. Marx A, et al. A striational muscle antigen and myasthenia gravis-associated thymomas share an acetylcholine receptor epitope. Dev Immunol 1992;2:77-84.
100. Bellone M, Karachunski PI, Ostlie N, Lei SJ, Conti-Tronconi BM. Preferential pairing of T and B cells for production of antibodies without covalent association of T and B epitopes. Eur J Immunol 1994;24:799-804.
101. Li ZY, Forester N, Vincent A. Modulation of acetylcholine receptor function in TE671 (rhabdomyosarcoma) cells by non-acetylcholine receptor ligands: possible relevance to seronegative myasthenia gravis. J Neuroimmunol 1996;64:179-183.
102. Wagner K, Edson K, Heginbotham L, Post M, Huganir RL, Czernik AJ. Determination of the tyrosine phosphorylation sites of the nicotinic acetylcholine receptor. J Biol Chem 1991;266:23784-23789.
103. Lindstrom J, Tzartos SJ, Gullick W. Structure and function of the acetylcholine receptor molecule studied using monoclonal antibodies. Ann N Y Acad Sci 1981;377:1-19.
104. Blatt Y, Montal MS, Lindstrom JM, Montal M. Monoclonal antibodies specific to the β and γ subunits of the Torpedo acetylcholine receptor inhibit single channel activity. J Neurosci 1986;6:481-486.
105. Huganir RL, Delcour AH, Greengard P, Hess GP. Phosphorylation of the nicotinic acetylcholine receptor regulates its rate of desensitization. Nature 1986;321:774-776.
106. Hopfield JF, Tank DW, Greengard P, Huganir RL. Functional modulation of the nicotinic acetylcholine receptor by tyrosine phosphorylation. Nature 1988;336:677-680.
107. Ferrer-Montiel AV, Montal MS, Diaz-Munoz M, Montal M. Agonist-independent activation of acetylcholine receptor channels by protein kinase A phosphorylation. Proc Natl Acad Sci USA 1991;88: 10213-10217.
108. Green WN, Ross AF, Claudio T. Acetylcholine receptor assembly is stimulated by phosphorylation of its gamma subunit. Neuron 1991;7:659-666.
109. Dipaola M, Czajkowski C, Karlin A. The sidedness of the cooh terminus of the acetylcholine receptor-delta-subunit. J Biol Chem 1989;264:15457-15463.
110. Chavez RA, Hall ZW. Expression of fusion proteins of the nicotinic acetylcholine receptor from mammalian muscle identifies the membrane-spanning regions in the alpha-subunit and delta-subunit. J Cell Biol 1992;116:385-393.
111. Tzartos SJ, Kordossi A. Acetylcholine receptor conformation probed by subunit-specific monoclonal antibodies. In: Maelicke A, ed. Nicotinic acetylcholine receptor. NATO.ASI.series. Vol H3. Heidelberg: Springer-Verlag; 1986. p. 35-47.
112. Kordossi A, Tzartos SJ. Conformation of cytoplasmic segments of acetylcholine receptor α and β subunits probed by monoclonal antibodies. Sensitivity of the antibody competition approach. EMBO J 1987;6:1605-1610.
113. Tzartos SJ, Kordossi A, Walgrave SL, Kokla A, Conti-Tronconi BM. Determination of antibody binding sites on the three-dimensional and primary structure of acetylcholine receptor. Monogr Allergy 1988;25:20-32.
114. Tzartos SJ, Hochschwender S, Vasquez P, Lindstrom J. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor. J Neuroimmunol 1987;15:185-194.
115. Conti-Tronconi B, Tzartos SJ, Lindstrom J. Monoclonal antibodies as probes of acetylcholine receptor structure. II. Binding to native receptor. Biochemistry 1981;20:2181-2191.
116. Tzartos SJ, Sophianos D, Efthimiadis A. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera. J Immunol 1985;134:2343-2349.
117. Kordossi AA, Tzartos SJ. Monoclonal antibodies against the main immunogenic region of the acetylcholine receptor - mapping on the intact molecule. J Neuroimmunol 1989;23:35-40.
118. Lennon VA, Lambert EH. Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors. Nature 1980;285:238-240.
119. Gomez CM, Richman DP. Anti-acetylcholine receptor antibodies directed against the α-bungarotoxin binding site induce a unique form of experimental myasthenia. Proc Natl Acad Sci USA 1983;80:4089-4093.
120. Mihovilovic M, Richman DP. Monoclonal antibodies as probes of the α-bungarotoxin and cholinergic binding regions of the acetylcholine receptor. J Biol Chem 1986;262:4978-4986.
121. Lukas RJ. Monoclonal rat anti-Torpedo electroplax nicotinic acetylcholine receptor antibodies: immunochemical characterization. J Immunol Methods 1984;74:129-138.
122. Kirvan CA, Zhu S, Richman D, Agius MA. Expression and initial characterization of recombinant/hybrid anti-acetylcholine receptor antibodies in experimental autoimmune myasthenia gravis. Ann N Y Acad Sci IX International Conference on Myasthenia Gravis and Related Disorders; 1998 (In press).
123. Whiting PJ, Vincent A, Schluep M, Newsom-Davis J. Monoclonal antibodies that distinguish between normal and denervated human acetylcholine receptor. J Neuroimmunol 1986;11:223-235.
124. Heidenreich F, Vincent A, Roberts A, Newsom-Davis J. Epitopes on human acetylcholine receptor defined by monoclonal antibodies and myasthenia gravis sera. Autoimmunity 1988;1:285-297.
125. Mochly-Rosen C, Fuchs S. Monoclonal anti-acetylcholine receptor antibodies directed against the cholinergic binding site. Biochemistry 1981;20:5920-5924.
126. Froehner S, Douville K, Klink S, Culp W. Monoclonal antibodies to cytoplasmic domains of the acetylcholine receptor. J Biol Chem 1983;258:7112-7120.
127. Watters D, Maelicke A. Organization of ligand binding sites at the acetylcholine receptor: a study with monoclonal antibodies. Biochemistry 1983;22:1811-1819.
128. Der Garabedian BV, Morel E. Monoclonal antibodies against the human acetylcholine receptor. Biochim Biophys Acta 1983;113:1-9.
129. Souroujon MC, Pachner AR, Fuchs S. The treatment of passively transferred experimental myasthenia with anti-idiotypic antibodies. Neurology 1986;36:622-625.
130. Tzartos SJ, Seybold M, Lindstrom J. Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc Natl Acad Sci USA 1982;79:188-192.
131. Jermy A, Beeson D, Vincent A. Pathogenic autoimmunity to affinity-purified mouse acetylcholine receptor induced without adjuvant in Balb/c mice. Eur J Immunol 1993;23:973-976.
132. Xu Q, DuPont BL, Fairdough RH, Richman DP. An anti-acetylcholine receptor monoclonal antibody that blocks agonist binding also modifies antibody binding to the main immunogenic region of the receptor. Neurology 1988;38 Suppl 1:135.
133. Loutrari H, Tzartos SJ, Claudio T. Use of Torpedo-mouse hybrid acetylcholine receptors reveals immunodominance of the alpha-subunit in myasthenia gravis antisera. Eur J Immunol 1992;22:2949-2956.
134. Loutrari H, Kokla A, Trakas N, Tzartos SJ. Expression of human-Torpedo hybrid acetylcholine receptor for analysing the subunit specificity of antibodies in sera from patients with myasthenia gravis. Clin Exp Immunol 1997;109:538-546.
135. Saedi MS, Anand R, Conroy WG, Lindstrom J. Determination of amino acids critical to the main immunogenic region of intact acetylcholine receptors by in vitro mutagenesis. FEBS Lett 1990;267:55-59.
136. Wang YD, Claudio T. Xenopus muscle acetylcholine receptor alpha-subunits bind ligands with different affinities. J Biol Chem 1993;268:18782-18793.
137. Luther MA, et al. A muscle acetylcholine receptor is expressed in the human cerebellar medulloblastoma cell line TE671. J Neurosci 1989;9:1082-1096.
138. Witzemann V, et al. Primary structure and functional expression of the alpha-subunit, beta-subunit, gamma-subunit, delta-subunit and epsilon-subunit of the acetylcholine receptor from rat muscle. Eur J Biochem 1990;194:437-448.
139. Beroukhim R, Unwin N. Three-dimensional location of the main immunogenic region of the acetylcholine receptor. Neuron 1995;15:323-331.
140. Kontou M, Vatzaki EH, Kokla A, Acharya KR, Oikonomakos NG, Tzartos SJ. Characterisation, crystallisation and preliminary X-ray diffraction analysis of a Fab fragment of a rat monoclonal antibody with very high affinity for the human muscle acetylcholine receptor. FEBS Lett 1996;389:195-198.
141. Ratnam M, et al. Location of antigenic determinants on primary sequences of the subunits of the nicotinic acetylcholine receptor by peptide mapping. Biochemistry 1986;25:2621-2632.
142. Barkas T, Gabriel JM, Juillerat M, Kokla A, Tzartos SJ. Localization of the main immunogenic region of the nicotinic acetylcholine receptor. FEBS Lett 1986;196:237-241.
143. Barkas T, Mauron A, Roth B, Alliod C, Tzartos SJ, Ballivet M. Mapping the main immunogenic region and toxin binding site of the nicotinic acetylcholine receptor. Science 1987;235:77-80.
144. Barkas T, et al. Fine localisation of the main immunogenic region of the nicotinic acetylcholine receptor to residues 61-76 of the α-subunit. J Biol Chem 1988;263:5916-5920.
145. Papadouli I, et al. Antigenic role of single residues within the main immunogenic region of the nicotinic acetylcholine receptor. Biochem J 1990;269:239-245.
146. Das MK, Lindstrom J. The main immunogenic region of the nicotinic acetylcholine receptor. Interaction of monoclonal antibodies with synthetic peptides. Biochem Biophys Res Commun 1989;165: 865-871.
147. Wood H, Beeson D, Vincent A, Newsom-Davis J. Epitopes on human acetylcholine receptor α-subunit: binding of monoclonal antibodies to recombinant and synthetic peptides. Biochem Soc Trans 1989;17:220-221.
148. Papadouli I, Sakarellos C, Tzartos SJ. High-resolution epitope mapping and fine antigenic characterization of the main immunogenic region of the acetylcholine receptor. Improving the binding activity of synthetic analogues of the region. Eur J Biochem 1993;211:227-234.
149. Bellone M, Tang F, Milius R, Conti-Tronconi BM. The main immunogenic region of the nicotinic acetylcholine receptor - identification of amino acid residues interacting with different antibodies. J Immunol 1989;143:3568-3579.
150. Wahlsten JL, Lindstrom JM, Conti-Tronconi BM. Amino acid residues within the sequence region-alpha-55-74 of Torpedo nicotinic acetylcholine receptor interacting with antibodies to the main immunogenic region and with snake alpha-neurotoxins. J Recept Res 1993;13:989-1008.
151. Clore GM, Gronenborn AM. Theory and applications of the transferred nuclear Overhauser effect to the study of the conformations of small ligands bound to proteins. J Magn Reson 1982;402-417.
152. Otting G. Experimental NMR techniques for studies of protein-ligand interaction. Curr Opin Struct Biol 1993;3:760-768.
153. Wuthrich K. Nuclear Overhauser enhancement (NOE) in biopolymers. In: NMR of protein and nucleic acids. New York: John Wiley and Sons; 1986. p. 93-113.
154. Cung MT, et al. 2D-1H NMR study of a synthetic peptide containing the main immunogenic region of the Torpedo acetylcholine receptor. Biopolymers 1989;28:465-478.
155. Cung MT, Marraud M, Tsikaris V, Sakarellos C, Papadouli I, Tzartos SJ. Antigen-antibody interactions study by 2D-1H NMR: molecular recognition between decapeptide analogues of the acetylcholine receptor α67-76 fragment and the anti-acetylcholine receptor antibody. J Chim Phys 1992;89:167-173.
156. Cung MT, et al. Two-dimensional H-1-NMR study of antigen-antibody interactions - binding of synthetic decapeptides to an anti-acetylcholine receptor monoclonal antibody. Biopolymers 1991;31:769-776.
157. Orlewski P, et al. Compared structures of the free nicotinic acetylcholine receptor main immunogenic region (MIR) decapeptide and the antibody-bound [A(76)]MIR analogue: a molecular dynamics simulation from two-dimensional NMR data. Biopolymers 1996;40:419-432.
158. Cung MT, et al. 2D-NMR and molecular dynamics analysis of the Torpedo californica acetylcholine receptor alpha-67-76 fragment and of its [Ala76]-analogue. Pept Res 1992;5:14-24.
159. Padlan EA. X-ray crystallography of antibodies. Adv Protein Chem 1995;49:57-132.
160. Tzartos SJ, Langeberg L, Hochschwender S, Lindstrom J. Demonstration of a main immunogenic region on acetylcholine receptors from human muscle using monoclonal antibodies to human receptor. FEBS Lett 1983;158:116-118.
161. Verschuuren JJ, Graus YM, Tzartos SJ, Vriesman PJ, DeBaets MH. Paratope-related and framework-related cross-reactive idiotopes on anti-acetylcholine receptor antibodies. J Immunol 1991;146:941-948.
162. Killen J, Hochschwender S, Lindstrom J. The MIR of acetylcholine receptors does not provoke the formation of antibodies to a predominant idiotype. J Neuroimmunol 1985;9:229-241.
163. Roberts A, Lang B, Vincent A. Newsom-Davis J. Search for cross-reactive idiotypes on monoclonal and myasthenia gravis acetylcholine receptor antibodies. Autoimmunity 1992;12:53-60.
164. Barkas T, Simpson JA. Lack of inter-animal cross-reaction of anti-acetylcholine receptor antibodies at the receptor-binding site as demonstrated by heterologous anti-idiotype anti-sera: implications for immunotherapy of myasthenia gravis. Clin Exp Immunol 1982;47:119-126.
165. Graus Y, Meng FP, Vincent A, Vriesman PV, Debaets M. Sequence analysis of anti-acetylcholine receptor antibodies in experimental autoimmune myasthenia gravis. J Immunol 1995;154:6382-6396.
166. Mamalaki A, Trakas N, Tzartos SJ. Bacterial expression of a single-chain Fv fragment which efficiently protects the acetylcholine receptor against antigenic modulation caused by myasthenic antibodies. Eur J Immunol 1993;23:1839-1845.
167. Graus YF, et al. Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies. J Immunol 1997;158:1919-1929.
168. Sophianos D, Tzartos SJ. Fab fragments of monoclonal antibodies protect the human acetylcholine receptor against degradation caused by myasthenic sera. J Autoimmun 1989;2:777-789.
169. Hohlfeld R, Toyka K, Tzartos SJ, Carson W, Conti-Tronconi B. Human T helper lymphocytes in myasthenia gravis recognize the nicotinic receptor α-subunit. Proc Natl Acad Sci USA 1987;84:5379-5383.
170. Whiting PJ, Vincent A, Newsom-Davis J. Myasthenia gravis: Monoclonal antihuman acetylcholine receptor antibodies used to analyse antibody specificities and responses to treatment. Neurology 1986;36:612-617.
171. Jacobson L, Vincent A, Beeson D. Subunit specificity of anti-acetylcholine receptor monoclonal antibody epitopes. Ann N Y Acad Sci IX International Conference on Myasthenia Gravis and Related Disorders; 1998 (In press).
172. Edberg CE, Black JL, Rome JD, Lennon VA. Acetylcholine receptor antibodies in tardive dyskinesias. Am J Psychiatry 1994;151:622-623.
173. Tzartos SJ. Monoclonal antibodies as probes of the acetylcholine receptor and myasthenia gravis. Trends Biochem Sci 1984;9:63-67.
174. Maelicke A, et al. Epitope mapping employing antibodies raised against short synthetic peptides: a study of the nicotinic acetylcholine receptor. Biochemistry 1989;28:1396-1405.
175. Vincent A, Jacobson L, Shillito P. Response to human acetylcholine receptor α138-199: determinant spreading initiates autoimmunity to self-antigen in rabbits. Immunol Lett 1994;39:269-275.
176. Agius MA, Twaddle GM, Fairclough RH. Epitope spreading in experimental
177. West AP, Bjorkman PJ, Dougherty DA, Lester HA. Expression and circular dichroism studies of the extracellular domain of the alpha subunit of the nicotinic acetylcholine receptor. J Biol Chem 1997;272:25468-25473.
178. Loutrari H, Kokla A, Tzartos SJ. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor. Eur J Immunol 1992;22:2449-2452.
179. Asher O, Kues WA, Witzemann V, Tzartos SJ, Fuchs S, Souroujon MC. Increased gene expression of acetylcholine receptor and myogenic factors in passively transferred experimental autoimmune myasthenia gravis. J Immunol 1993;151:6442-6450.
180. Barchin D, Asher O, Tzartos SJ, Fuchs S, Souroujon MC. Modulation of the anti-acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor. Eur J Immunol 1998 (In press).
181. Gomez CM, Richman DP. Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis. J Immunol 1985;135:234-241.
182. Tzartos SJ, Starzinski-Powitz A. Decrease in acetylcholine receptor content of human myotube cultures mediated by monoclonal antibodies to α, β, and γ subunits. FEBS Lett 1986;196:91-95.
183. Tzartos SJ, et al. The main immunogenic region of the acetylcholine receptor - structure and role in myasthenia gravis. Autoimmunity 1991;8:259-270.
184. Conti-Fine BM, Lei SJ, McLane KE. Antibodies as tools to study the structure of membrane proteins: the case of the nicotinic acetylcholine receptor. Annu Rev Biophys Biomol Struct 1996;25: 197-229.
185. Merlie JP, Smith MM. Synthesis and assembly of acetylcholine receptor, a multisubunit membrane glycoprotein. J Membr Biol 1986;91:1-10.
186. Tzartos SJ, Changeux J-P. Lipid-dependent recovery of α-bungarotoxin and monoclonal antibody binding to the purified α-subunit from Torpedo marmorata acetylcholine receptor. J Biol Chem 1984;259:11512-11519.
187. Paulson HL, Claudio T. Temperature-sensitive expression of all-Torpedo and Torpedo- rat hybrid acetylcholine receptor in mammalian muscle cells. J Cell Biol 1990;110:1705-1717.
188. Araga S, Leboeuf RD, Blalock JE. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor. Proc Natl Acad Sci USA 1993;90:8747-8751.
189. Araga S, Galin FS, Kishimoto M, Adachi A, Blalock JE. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptor. J Immunol 1996;157:386-392.
190. Lee SW, Sullenger BA. Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies. Nat Biotechnol 1997;15:41-45.
191. Tzartos SJ, Tsantili P, Papanastasiou D, Mamalaki A. Construction of single-chain Fv fragments of anti-MIR monoclonal antibodies. Ann N Y Acad Sci IX International Conference on Myasthenia Gravis and Related Disorders; 1998 (In press).
192. Vatzaki EH, Acharya KR, Oikonomakos NG, Tzartos SJ. Crystallization and preliminary crystallographic study of an Fab fragment of a pathogenic rat monoclonal antibody against the nicotinic acetylcholine receptor. Protein Sci 1993;2:1770-1772.
193. Blair DA, Mihovilovic M, Agius MA, Fairclough RH, Richman DP. Human X human hybridomas from patients with myasthenia gravis: possible tools for idiotypic therapy for myasthenia gravis. Ann N Y Acad Sci 1987;505:155-167.
194. Lefvert AK, Holm G, Pirskanen R. Autoantiidiotypic antibodies in myasthenia gravis. Ann N Y Acad Sci 1987;505:133-154.
195. Cardona A, Garchon HJ, Vernet-der Garabedian B, Morel E, Gajdos P, Bach JF. Human IgG monoclonal autoantibodies against muscle acetylcholine receptor: direct evidence for clonal heterogeneity of the antiself humoral response in myasthenia gravis. J Neuroimmunol 1994;53:9-16.
196. Farrar J, et al. Diverse Fab specific for acetylcholine receptor epitopes from a myasthenia gravis thymus combinatorial library. Int Immunol 1997;9:1311-1318.
197. Matthews I, et al. Production of Fab fragments against the human acetylcholine receptor from myasthenia gravis thymus lambda and kappa phage libraries. Ann N Y Acad Sci IX International Conference on Myasthenia Gravis and Related Disorders; 1998 (In press).
198. Wilson PT, Hawrot E, Lentz TL. Distribution of α-bungarotoxin binding sites over residues 173-204 of the α subunit of the acetylcholine receptor. Mol Pharmacol 1988;34:643-650.
199. Gotti C, Frigerio F, Bolognesi M, Longhi R, Racchetti G, Clementi F. Nicotinic acetylcholine receptor: a structural model for α-subunit peptide 188-201, the putative binding site for cholinergic agents. FEBS Lett 1988;228:118-122.
200. Kachalsky SG, Jensen BS, Barchan D, Fuchs S. Two subsites in the binding domain of the acetylcholine receptor: an aromatic subsite and a proline subsite. Proc Natl Acad Sci USA 1995;92: 10801-10805.
201. Barkas T, Gairns J Mc, Kerr HJ, Coggins JR, Simpson JA. α-bungarotoxin binding to the nicotinic acetylcholine receptor is inhibited by two distinct subpopulations of anti-receptor antibodies. Eur J Biochem 1982;12:757-761.
202. Barkas T, Simpson JA. α-bungarotoxin displacing antibody in myasthenia gravis. J Clin Lab Immunol 1982;9:113-117.
203. Dowding AJ, Hall ZW. Monoclonal antibodies specific for each of the two toxin-binding sites of Torpedo acetylcholine receptor. Biochemistry 1987;26:6372-6381.
204. Conti-Tronconi BM, Tang F, Diethelm BM, Spencer SR, Reinhardt Maelicke S, Maelicke A. Mapping of a cholinergic binding site by means of synthetic peptides, monoclonal antibodies, and alpha-bungarotoxin. Biochemistry 1990;29:6221-6230.
205. Fels G, Plumer-Wilk R, Schreiber M, Maelicke A. A monoclonal antibody interfering with binding and response of the acetylcholine receptor. J Biol Chem 1986;261:15746-15754.
206. Bufler J, Kahlert S, Tzartos S, Toyka KV, Maelicke A, Franke C. Activation and blockade of mouse muscle nicotinic channels by antibodies directed against the binding site of the acetylcholine receptor. J Physiol (Lond) 1996;492:107-114.
207. Conti Tronconi BM, et al. Alpha-bungarotoxin and the competing antibody WF6 interact with different amino acids within the same cholinergic subsite. Biochemistry 1991;30:2575-2584.
208. Schroder B, et al. Monoclonal antibodies Fk1 and Wf6 define two neighboring ligand binding sites on Torpedo acetylcholine receptor alpha-polypeptide. J Biol Chem 1994;269:10407-10416.
209. Donnelly D, Mihovilovic M, Gonzalez-Ros JM, Ferragut JA, Richman D, Martinez-Carrion M. A noncholinergic site-directed monoclonal antibody can impair agonist-induced ion flux in Torpedo californica acetylcholine receptor. Proc Natl Acad Sci USA 1984;81:7999-8003.
210. Mihovilovic M, Richman DP. Modification of α-bungarotoxin and cholinergic ligand-binding properties of Torpedo acetylcholine receptor by an anti-acetylcholine receptor monoclonal antibody. J Biol Chem 1984;259:15051-15059.
211. Chinchetru MA, Marquez J, Garcia-Borron JC, Richman DP, Martinez-Carrion M. Interaction of nicotinic acetylcholine receptor with 2 monoclonal antibodies recognizing different epitopes. Biochemistry 1989;28:4222-4229.
212. Mihovilovic M, Donnelly-Roberts D, Richman DP, Martinez-Carrion M. Pathogenesis of hyperacute experimental autoimmune myasthenia gravis. J Immunol 1994;152:5997-6002.
213. Chase BA, Holliday J, Reese JH, Chun LL, Hawrot E. Monoclonal antibodies with defined specificities for Torpedo nicotinic acetylcholine receptor cross-react with drosophila neural tissue. Neuroscience 1987;21:959-976.
214. Cleveland WL, Wassermann NH, Sarangarajan R, Penn AS, Erlanger BF. Monoclonal antibodies to the acetylcholine receptor by a normally functioning auto-anti-idiotypic mechanism. Nature 1983;305:56-57.
215. Vernet-der Garabedian B, Morel E, Bach JF. Heterogeneity of antibodies directed against the alpha-bungarotoxin binding site on human acetylcholine receptor and severity of myasthenia gravis. J Neuroimmunol 1986;12:65-74.
216. Bellone M, Ostlie N, Karachunski P, Manfredi AA, Conti-Tronconi BM. Cryptic epitopes on the nicotinic acetylcholine receptor are recognized by autoreactive CD4(+) cells. J Immunol 1993;151:1025-1038.
217. Vernet-der Garabedian B, Eymard B, Bach J-F, Morel E. Alpha-bungarotoxin blocking antibodies in neonatal myasthenia gravis: frequency and selectivity. J Neuroimmunol 1989;21:41-47.
218. Eymard B, Vernet-der Garabedian B, Berrih-Aknin S, Pannier C, Bach JF, Morel E. Anti-acetylcholine receptor antibodies in neonatal myasthenia gravis - heterogeneity and pathogenic significance. J Autoimmun 1991;4:185-195.
219. Maricq AV, Gu Y, Hestrin S, Hall Z. The effects of a myasthenic serum on the acetylcholine receptors of C2 myotubes. II. Functional inactivation of the receptor. J Neurosci 1985;5:1917-1924.
220. Lang B, Richardson G, Rees J, Vincent A, Newsom-Davis J. Plasma from myasthenia gravis patients reduces acetylcholine receptor agonist-induced Na+ flux into TE671 cell line. J Neuroimmunol 1988;19:141-148.
221. Schuetze SM, Vicini S, Hall ZW. Myasthenic serum selectively blocks acetylcholine receptors with long channel open times at developing rat endplates. Proc Natl Acad Sci USA 1985;82:2533-2537.
222. Bufler J, Wilhelm R, Parnas H, Franke C, Dudel J. Open channel and competitive block of the embryonic form of the nicotinic receptor of mouse myotubes by (+)-tubocurarine. J Physiol (Lond) 1996;495:83-95.
223. Mulac-Jericevic B, Kurisaki J-I, Atassi MZ. Profile of the continuous antigenic regions on the extracellular part of the α chain of an acetylcholine receptor. Proc Natl Acad Sci USA 1987;84:3633-3637.
224. Sano M, McCormick DJ, Talib S, Griesmann GE, Lennon VA. Identification of three extended antibody-binding segments in recombinant human muscle acetylcholine receptor alpha-subunit extracellular domain 1-210. Int Immunol 1991;3:983-989.
225. Lennon V, McCornick D, Lambert E, Griesmann G, Atassi M. Region of peptide 125-147 of acetylcholine receptor α subunits is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis, T-cell immunity, and modulating autoantibodies. Proc Natl Acad Sci USA 1985;82:8805-8809.
226. Ashizawa T, Ruan KH, Jinnai K, Atassi MZ. Profile of the regions on the alpha-chain of human acetylcholine receptor recognized by autoantibodies in myasthenia gravis. Mol Immunol 1992;29:1507-1514.
227. Vernet-der Garabedian B, et al. Association of neonatal myasthenia gravis with antibodies against the fetal acetylcholine receptor. J Clin Invest 1994;94:555-559.
228. Gardnerova M, et al. The fetal/adult acetylcholine receptor antibody ratio in mothers with myasthenia gravis as a marker for transfer of the disease to the newborn. Neurology 1997;48:50-54.
229. Riemersma S, et al. Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. J Clin Invest 1996;98:2358-2363.
230. Aarli JA. Myasthenia gravis and thymoma. In: Lisak RP, ed. Handbook of myasthenia gravis and myasthenic syndromes. New York: Dekker; 1994. p. 207-224.
231. Williams CL, Hay JE, Huiatt TW, Lennon VA. Paraneoplastic IgG striational autoantibodies produced by clonal thymic-B cells and in serum of patients with myasthenia-gravis and thymoma react with titin. Lab Invest 1992;66:331-336.
232. Mappouras DG, et al. Antibodies to acetylcholinesterase cross-reacting with thyroglobulin in myasthenia gravis and Graves' disease. Clin Exp Immunol 1995;100:336-343.
233. Stefansson K, Dieperink ME, Richman DP, Gomez CM, Marton LS. Sharing of antigenic determinants between the nicotinic acetylcholine receptor and proteins in Escherichia coli, Proteus vulgaris, and Klebsiella pneumoniae. N Engl J Med 1985;312:221-225.
234. Dieperink ME, Stefansson K. Molecular mimicry and microorganisms: a role in the pathogenesis of myasthenia gravis? Curr Top Microbiol Immunol 1989;145: 57-65.
235. Schwimmbeck PL, Dyrberg T, Drachman DB, Oldstone MB. Molecular mimicry and myasthenia gravis - an autoantigenic site of the acetylcholine receptor alpha-subunit that has biologic activity and reacts immunochemically with herpes simplex virus. J Clin Invest 1989;84:1174-1180.
236. Manfredi AA, Bellone M, Protti MP, Conti Tronconi BM. Molecular mimicry among human autoantigens [letter]. Immunol Today 1991;12:46-47.
237. Mohan S, Barohn RJ, Krolick KA. Unexpected cross-reactivity between myosin and a main immunogenic region of the acetylcholine receptor by antisera obtained from myasthenia gravis patients. Clin Immunol Immunopathol 1992;64: 218-226.
238. Mohan S, Barohn RJ, Jackson CE, Krolick KA. Evaluation of myosin-reactive antibodies from a panel of myasthenia gravis patients. Clin Immunol Immunopathol 1994;70: 266-273.
239. Noda M, et al. Cloning and sequence analysis of calf cDNA and human genomic DNA encoding α subunit precursor of muscle acetylcholine receptor. Nature 1983;305:818-823.